An interventional study of lipodia in Hypercholesterolemia and Dyslipidemias, sponsored by Gaia AG. Completed at 1 site in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-07.
Sponsored by Gaia AG · Not applicable, Interventional, and Treatment
The goal of this clinical trial is to find out if lipodia, a digital health intervention, can help lower cholesterol levels and improve other health measures in adults with high cholesterol.
The main questions it aims to answer are:
Researchers will compare two groups:
Participants will:
Exclusion criteria
Participants allocated to the intervention group will receive access to lipodia in addition to treatment as usual (TAU). lipodia is a digital health application designed for individuals with hypercholesterinemia, accessible through a web browser. The application focuses on treatment methods derived health behavior change and cognitive behavioral therapy (CBT). Topics addressed by lipodia are activity planning and impulse control, dietary habits, physical activity, stress management, mood management, sleep management, weight management, as well as quitting smoking and drinking. The program operates through interactive "dialogues", which are accompanied by illustrations, audio recordings, motivating text messages, worksheets, and summaries. Users are also encouraged to regularly complete short questionnaires to monitor their complaints. Once registered, the program remains accessible for 365 days.
Behavioral: lipodia
Participants allocated to the control group will receive access to treatment as usual (TAU).
Participants will receive access to the digital health intervention lipodia in addition to TAU.
Fasting LDL-C levels
Time frame: 6 months
Patients' activation
Assessed with the total score of the PAM-13. Higher scores indicate higher patient activation (better outcome).
Time frame: 6 months
Fasting non-HDL-C levels
Time frame: 6 months
Health-related quality of life
Assessed with the total score of the AQoL-8D. Higher scores indicate higher quality of life (better outcome).
Time frame: 6 months
BMI
Time frame: 6 months
Fasting triglyceride levels
Time frame: 6 months
Fasting HDL-C levels
Time frame: 6 months
Fasting LDL-C levels
Time frame: 3 months
Patients' activation
Assessed with the total score of the PAM-13. Higher scores indicate higher patient activation (better outcome).
Time frame: 3 months
Fasting non-HDL-C levels
Time frame: 3 months
Health-related quality of life
Assessed with the total score of the AQoL-8D. Higher scores indicate higher quality of life (better outcome).
Time frame: 3 months
BMI
Time frame: 3 months
Fasting triglyceride levels
Time frame: 3 months
Fasting HDL-C levels
Time frame: 3 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Gaia AG